What is the ROE (Return on Equity) of Cyclopharm this year?
The ROE of Cyclopharm this year is -0.15 undefined.
Cyclopharm ROE 2025
Cyclopharm ROE
-0.15
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2025, Cyclopharm's return on equity (ROE) was -0.15, a -19.47% increase from the -0.18 ROE in the previous year.
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Cyclopharm's Return on Equity (ROE)
Cyclopharm's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Cyclopharm's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Cyclopharm's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Cyclopharm’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Cyclopharm stock
How has the Return on Equity (ROE) of Cyclopharm developed compared to the previous year?
The ROE of Cyclopharm has increased by -19.47% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Cyclopharm?
A high ROE indicates that Cyclopharm generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Cyclopharm?
A low ROE can indicate that Cyclopharm is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Cyclopharm affect the company?
A change in ROE (Return on Equity) of Cyclopharm can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Cyclopharm?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Cyclopharm?
Some factors that can influence Cyclopharm's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 0.62 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.01 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 0.62 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 0 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to 0.01 AUD are expected. This corresponds to a dividend yield of 0.56 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2024?
In the year 2024, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
